• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600222.SS
Share

Henan Taloph Pharmaceutical Stock Co.,Ltd Stocks

CN¥ 7.3Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 611.70M

CN¥ 7.3
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating from Zhengzhou, China, Henan Taloph Pharmaceutical Stock Co., Ltd. specializes in the research, development, production, and sale of a wide array of Chinese and Western medicines across the nation. The company's product line encompasses various forms, such as oral liquids, tablets, capsules, and injectable fluids. Notable products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, and pazufloxacin mesylate sodium chloride injections, alongside a selection of other infusion products. Taloph Pharmaceutical serves a diverse client base, including hospitals, pharmacies, and direct consumers. It was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 22:06

Apple shares received a rare "sell" recommendation. An analyst identified risks to demand

14.07.2026 21:33

SpaceX will become the internet provider for Frontier flights. Why this matters

14.07.2026 20:52

BofA recommended selling Papa John's stock. What raised analysts' concerns?

14.07.2026 20:41

Trump has lifted the requirement for ships to pay a toll to pass through the Strait of Hormuz

14.07.2026 19:14

"Life is unpredictable": Buffett has set a deadline for distributing his shares

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026